Bokf Na Increases Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Bokf Na grew its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 18.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,280 shares of the biopharmaceutical company’s stock after buying an additional 2,844 shares during the quarter. Bokf Na’s holdings in Royalty Pharma were worth $547,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Fidelis Capital Partners LLC purchased a new stake in shares of Royalty Pharma during the 1st quarter valued at about $46,000. GAMMA Investing LLC raised its position in shares of Royalty Pharma by 172.5% during the 1st quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 1,037 shares in the last quarter. Allworth Financial LP raised its position in shares of Royalty Pharma by 76.7% during the 4th quarter. Allworth Financial LP now owns 1,684 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 731 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in Royalty Pharma by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 802 shares during the period. Finally, Lindbrook Capital LLC raised its position in Royalty Pharma by 485.2% in the 4th quarter. Lindbrook Capital LLC now owns 2,411 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 1,999 shares during the period. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RPRX has been the topic of a number of research analyst reports. Morgan Stanley upped their target price on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, July 11th. StockNews.com downgraded shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Bank of America lowered their target price on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, April 12th. Finally, UBS Group downgraded shares of Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 target price for the company. in a research note on Monday, June 3rd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Royalty Pharma currently has an average rating of “Moderate Buy” and a consensus price target of $41.80.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock traded down $0.07 on Monday, hitting $28.72. The company’s stock had a trading volume of 212,580 shares, compared to its average volume of 2,648,125. The company has a debt-to-equity ratio of 0.62, a quick ratio of 12.52 and a current ratio of 12.52. Royalty Pharma plc has a 1 year low of $25.20 and a 1 year high of $31.66. The firm has a fifty day moving average price of $26.98 and a 200-day moving average price of $28.39. The company has a market capitalization of $17.16 billion, a price-to-earnings ratio of 21.49, a price-to-earnings-growth ratio of 3.78 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.02. Royalty Pharma had a return on equity of 22.94% and a net margin of 35.70%. The firm had revenue of $568.00 million during the quarter, compared to analyst estimates of $671.45 million. During the same quarter in the previous year, the business earned $1.60 EPS. As a group, sell-side analysts anticipate that Royalty Pharma plc will post 4.01 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 13th. Stockholders of record on Friday, August 16th will be issued a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 2.92%. The ex-dividend date of this dividend is Friday, August 16th. Royalty Pharma’s dividend payout ratio is currently 62.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.